In this session, to define the risk of recurrence there are multi-factors like tumor size, lymph node status, age, and genetic testing in assessing the risk for hormone receptor-positive early breast cancer patients.
In Part I, focuses on the impact of tumor size and lymph node status on high and low risk. A cross-generational study involving 151 clinical trials and over 150,000 patients shows that recurrence risk persists over time despite advancements in medication.
Although the more lymph node metastasis, the higher the recurrence risk, a 2024 ASCO retrospective study from MSKCC indicates a 3-year recurrence risk of 8.5% and a 5-year risk of 17.4% and 7 year risk of 25.7 in re-define high risk N0 population.
In part 2, focuses on discussing the impact of age and genetic testing on the risk for hormone receptor-positive early breast cancer patients.
Age is a significant prognostic factor, with younger patients having relatively poorer prognosis.
Genetic tests (e.g., Oncotype DX, MammaPrint, Prosigna, EndoPredict, Breast Cancer Index) are used to predict patient risk and guide treatment decisions.
Personalized treatment plans are developed based on age and genetic test results with more consideration treatment schedule needed.
台灣諾華股份有限公司
台灣諾華承續全球的目標和願景，以研發創新藥品來治療疾病、減輕疾病帶來的痛苦，並提昇病患的生活品質。期望符合甚且超越外界期許，致力創造永續成長，保持業界前茅，維持長期經營成效。希望贏得優異工作環境的美譽、營造鼓勵創新與效率的環境，並能適時回饋社會。